SCHEMBL380500

SCHEMBL380500

COC(=O)[C@H]1CC[C@@H](N)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
PPM1B O75688 1/20 0.44
PTPN1 P18031 1/20 0.44
PPP1CC P36873 1/20 0.44
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA7 P36544 1/20 0.42
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
MMP2 P08253 1/20 0.40
ANPEP P15144 1/20 0.40
BRD4 O60885 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL363035 1.00 TP53 (0.47) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
SCHEMBL473626 1.00 TP53 (0.47) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
Hydrochloric Acid SCHEMBL363034 0.98 TP53 (0.46) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
Hydrochloric Acid SCHEMBL363033 0.98 TP53 (0.46) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
Hydrochloric Acid SCHEMBL1178819 0.98 TP53 (0.46) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
SCHEMBL24475220 0.92 SMN1; SMN2 (0.47) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
SCHEMBL22096230 0.92 SMN1; SMN2 (0.51) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
SCHEMBL19910371 0.90 SMN1; SMN2 (0.54) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
Sulfuric Acid SCHEMBL27596525 0.88 TP53 (0.47) TP53SMN1; SMN2PPM1BPTPN1PPP1CC
SCHEMBL13245964 0.88 TP53 (0.40) TP53SMN1; SMN2PPM1BPTPN1PPP1CC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2025-06-24 US disclosed
CN-119954777-A 2, 4-Diaminopyrimidine compound and application thereof 沈阳药科大学 2025-05-09 CN disclosed
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 WO disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 WO disclosed
US-12084445-B2 Broad-spectrum carbapenems VenatoRx Pharmaceuticals, Inc. (US) 2024-09-10 US disclosed
US-20240287020-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2024-08-29 US disclosed
US-11970474-B2 Substituted benzodiazoles and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2024-04-30 US disclosed
CN-112074511-B Substituted benzodiazoles and their use in therapy 托马斯·黑勒戴药物研究基金会 2024-04-26 CN disclosed
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 US disclosed
EP-1732882-A1 NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS Revotar Biopharmaceuticals AG (DE) 2006-12-20 EP disclosed
US-20060281712-A1 Pyrimidine compounds TAIGEN BIOTECHNOLOGY (TW) 2006-12-14 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
WO-2005090284-A1 NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS REVOTAR BIOPHARMACEUTICALS AG (DE) 2005-09-29 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed
US-5691321-A INSECTICIDES, MITICIDES, PARASITICIDES HOECHST SCHERING AGREVO GMBH (DE) 1997-11-25 US disclosed
CN-1148383-A Heterocyclylamino-and heterocyclyloxy-cycloalkyl derivatives, their preparation and their use as pesticides and fungicides HOECHST SCHERING AGREVO GMBH (DE) 1997-04-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281712-A1 Pyrimidine compounds TYMS, TYMP, HPRT1 TP53 625/4885SMN1; SMN2 252/4885PPM1B 1134/4885
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 TP53 3952/4885SMN1; SMN2 3702/4885PPM1B 1705/4885
US-11970474-B2 Substituted benzodiazoles and use thereof in therapy XDH, CYP4X1, CYP11B2 TP53 2748/4885SMN1; SMN2 1674/4885PPM1B 3720/4885
US-20240287020-A1 SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY XDH, CYP11B2, CYP4X1 TP53 2912/4885SMN1; SMN2 1434/4885PPM1B 3592/4885
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 TP53 111/4885SMN1; SMN2 1414/4885PPM1B 56/4885
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 TP53 3821/4885SMN1; SMN2 4611/4885PPM1B 3353/4885
US-12084445-B2 Broad-spectrum carbapenems MGAM, ALPI, SI TP53 4728/4885SMN1; SMN2 2268/4885PPM1B 1271/4885
US-12338226-B2 Substituted benzodiazoles and use thereof in therapy XDH, CYP11B2, CYP4X1 TP53 2912/4885SMN1; SMN2 1434/4885PPM1B 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.